ASTX660, an antagonist of cIAP1/2 and XIAP, increases antigen processing machinery and can enhance radiation-induced immunogenic cell death in preclinical models of head and neck cancer
Inhibitor of apoptosis protein (IAP) antagonists have shown activity in preclinical models of head and neck squamous cell carcinoma (HNSCC), and work across several cancer types has demonstrated diverse immune stimulatory effects including enhancement of T cell, NK cell, and dendritic cell function....
Main Authors: | Wenda Ye, Sreenivasulu Gunti, Clint T. Allen, Youji Hong, Paul E. Clavijo, Carter Van Waes, Nicole C. Schmitt |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2020-01-01
|
Series: | OncoImmunology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/2162402X.2019.1710398 |
Similar Items
-
The non‐peptidomimetic IAP antagonist ASTX660 sensitizes colorectal cancer cells for extrinsic apoptosis
by: Gertrud Knoll, et al.
Published: (2021-03-01) -
Loss of cIAP1 in Endothelial Cells Limits Metastatic Extravasation through Tumor-Derived Lymphotoxin Alpha
by: Lazaros Vasilikos, et al.
Published: (2021-02-01) -
The SMAC mimetic AT-101 exhibits anti-tumor and anti-metastasis activity in lung adenocarcinoma cells by the IAPs/ caspase-dependent apoptosis and p65-NFƙB cross-talk
by: Irfan Ahmad, et al.
Published: (2021-07-01) -
Future Therapeutic Directions for Smac-Mimetics
by: Emma Morrish, et al.
Published: (2020-02-01) -
Regulation of the Cellular Inhibitor of Apoptosis 1 (cIAP1) Translation by IRES Trans-Acting Factors and Impact on Cancer
by: Faye, Mame Daro
Published: (2015)